219 related articles for article (PubMed ID: 2459005)
21. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
Kuziej J; Litinas E; Hoppensteadt DA; Liu D; Walenga JM; Fareed J; Jeske W
Clin Appl Thromb Hemost; 2010 Aug; 16(4):377-86. PubMed ID: 20460347
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological actions of sulodexide.
Ofosu FA
Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis--evidence for an anticoagulant-independent mechanism.
Barbanti M; Calanni F; Milani MR; Marchi E; Semeraro N; Colucci M
Thromb Haemost; 1993 Feb; 69(2):147-51. PubMed ID: 8456427
[TBL] [Abstract][Full Text] [Related]
24. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
Diquélou A; Dupouy D; Cariou R; Sakariassen KS; Boneu B; Cadroy Y
Thromb Haemost; 1995 Nov; 74(5):1286-92. PubMed ID: 8607111
[TBL] [Abstract][Full Text] [Related]
25. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
[TBL] [Abstract][Full Text] [Related]
26. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
[TBL] [Abstract][Full Text] [Related]
27. [A comparative study of the action of preparations of high- and low-molecular weight heparin on hemostatic indices in vitro and in their intravenous administration to animals].
Kudriashov BA; Pastorova VE; Liapina LA; Kondashevskaia MV; Azieva LD; Sukhanov IuS; Fedeniuk PV; Vasiukov SE; Cherstvova LG
Eksp Klin Farmakol; 1992; 55(1):35-8. PubMed ID: 1339042
[TBL] [Abstract][Full Text] [Related]
28. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model.
Ao PY; Hawthorne WJ; Coombs R; Fletcher JP
Int Angiol; 1999 Jun; 18(2):131-9. PubMed ID: 10424369
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the effects of low-molecular-weight and unfractioned heparin in horses.
Monreal L; Villatoro AJ; Monreal M; Espada Y; Anglés AM; Ruiz-Gopegui R
Am J Vet Res; 1995 Oct; 56(10):1281-5. PubMed ID: 8928943
[TBL] [Abstract][Full Text] [Related]
30. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.
Bratt G; Törnebohm E; Granqvist S; Aberg W; Lockner D
Thromb Haemost; 1985 Dec; 54(4):813-7. PubMed ID: 3911482
[TBL] [Abstract][Full Text] [Related]
31. Antithrombotic and bleeding effects of a new synthetic direct thrombin inhibitor and of standard heparin in the rabbit.
Cadroy Y; Caranobe C; Bernat A; Maffrand JP; Sié P; Boneu B
Thromb Haemost; 1987 Aug; 58(2):764-7. PubMed ID: 3672429
[TBL] [Abstract][Full Text] [Related]
32. The venous antithrombotic effect of LF 1351 in the rat following oral administration.
Millet J; Theveniaux J; Brown NL
Thromb Haemost; 1992 Jan; 67(1):176-9. PubMed ID: 1615473
[TBL] [Abstract][Full Text] [Related]
33. Antithrombotic and thrombolytic activity of heparins in a rat model of laser-induced thrombosis.
Krupiński K; Giedrojć J; Breddin HK; Bielawiec M
Pol J Pharmacol; 1996; 48(3):345-50. PubMed ID: 9112675
[TBL] [Abstract][Full Text] [Related]
34. Anticoagulant and antithrombotic activities of a chemically sulfated galactoglucomannan obtained from the lichen Cladonia ibitipocae.
Martinichen-Herrero JC; Carbonero ER; Sassaki GL; Gorin PA; Iacomini M
Int J Biol Macromol; 2005 Mar; 35(1-2):97-102. PubMed ID: 15769521
[TBL] [Abstract][Full Text] [Related]
35. Low affinity heparin is an antithrombotic agent.
Gray E; Cesmeli S; Lormeau JC; Davies AB; Lane DA
Thromb Haemost; 1994 Feb; 71(2):203-7. PubMed ID: 8191399
[TBL] [Abstract][Full Text] [Related]
36. Antithrombotic effect of OP/LMWH by subcutaneous route in rats.
Fantuz M; Milani R; Andriuoli G; Mastacchi R; Barbanti M
Arch Int Pharmacodyn Ther; 1986 Aug; 282(2):328-34. PubMed ID: 3767531
[TBL] [Abstract][Full Text] [Related]
37. Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities.
Fonseca RJ; Oliveira SN; Melo FR; Pereira MG; Benevides NM; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):539-45. PubMed ID: 18327402
[TBL] [Abstract][Full Text] [Related]
38. Time-course of anti-Xa effects of calcium heparin and low-molecular-weight heparin given s.c.: insights for thrombosis prevention.
Romeo G; Salanitri G; Catania G
Drugs Exp Clin Res; 1988; 14(6):423-7. PubMed ID: 2850903
[TBL] [Abstract][Full Text] [Related]
39. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
Berry CN; Girard D; Lochot S; Lecoffre C
Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
[TBL] [Abstract][Full Text] [Related]
40. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
